Effects Of Besifloxacin Drug! Trivia Facts Quiz

10 Questions | By Wyanoke | Updated: Mar 20, 2022 | Attempts: 34

Questions

Settings

Create your own Quiz

Effects Of Besifloxacin Drug! Trivia Facts Quiz - Quiz

Questions and Answers

1.

The besifloxacin molecule has been modified from what basic molecular structure to increase potency against and minimize the resistance of bacterial targets?^1-3 The clinical significance of these in vitro data has not been established. In vitro studies demonstrated cross-resistance between BESIVANCE^® and some fluoroquinolones. In vitro resistance to BESIVANCE develops via multiple-step mutations and occurs at a general frequency of <3.3x 10^-10 for Staphylococcus aureus and <7 x 10^-10 for Streptococcus pneumonia.
- A.
  
  Quinolone
- B.
  
  Aminoglycoside
- C.
  
  Macrolide
2.

The addition of an N1 cyclopropyl moiety to the basic quinolone structure increased lethality by what mechanism?⁴ The clinical significance of these in vitro data has not been established.
- A.
  
  It binds to cleaved DNA only
- B.
  
  It binds to DNA gyrase only
- C.
  
  It binds to the enzyme-DNA pocket
3.

Which 2 halogens contribute to the potency and broad-spectrum efficacy of besifloxacin^®?^3,5 The clinical significance of these in vitro data has not been established.
- A.
  
  Chlorine and bromine
- B.
  
  Bromine and fluorine
- C.
  
  Chlorine and fluorine
4.

By what factor of the inhibition of DNA gyrase increased when a fluorine molecule is added to the C6 position of the basic quinolone structure?¹ The clinical significance of these in vitro data has not been established.
- A.
  
  2X
- B.
  
  5X
- C.
  
  10X
5.

Besifloxacin contains a C6 fluorine molecule, which improves activity against which bacterial type?¹ The clinical significance of these in vitro data has not been established.
- A.
  
  Gram-positive bacteria
- B.
  
  Gram-negative bacteria
- C.
  
  Both gram-negative and gram-positive bacteria
6.

Early addition of a bulky piperazine ring to the C7 position of the basic quinolone structure improved activity against which organisms?¹ The clinical significance of these in vitro data has not been established.
- A.
  
  Gram-positive bacteria
- B.
  
  Gram-negative bacteria
- C.
  
  Anaerobic bacteria
7.

To which position was a chlorine molecule added to make BESIVANCE® a chlorofluoroquinolone with increased potency?³ Clinical significance of these in vitro data has not been established.
- A.
  
  C8
- B.
  
  C9
- C.
  
  C10
8.

BESIVANCE^® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of which bacterial species?⁶ BESIVANCE^® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarus* *Efficacy for this organism was studied in fewer than 10 infections.
- A.
  
  Aerococcus viridans, Pseudomonas aeruginosa, and Moraxella catarrhaslis
- B.
  
  Staphylococcus aureus and Staphylococcus epidermidis
- C.
  
  Both choices A and B, among others. Please see prescribing information for complete indication.
9.

The dually halogenated structure of BESIVANCE® confers potent and balanced inhibition of which 2 bacterial enzymes?^6,9,10 Clinical significance of these in vitro data has not been established. In vitro studies demonstrated cross-resistance between BESIVANCE^® and some fluoroquinolones. In vitro resistance to BESIVANCE develops via multiple-step mutations and occurs at a general frequency of <3.3x 10^-10 for Staphylococcus aureus and <7 x 10^-10 for Streptococcus pneumoniae.
- A.
  
  DNA polymerase I and DNA ligase
- B.
  
  Helicase and primase
- C.
  
  DNA gyrase and topoisomerase IV
10.

At minimum, how many mutations must a bacterium accumulate to develop significant levels of resistance to BESIVANCE^®?¹¹ Clinical significance of these in vitro data has not been established. In vitro studies demonstrated cross-resistance between BESIVANCE^® and some fluoroquinolones. In vitro resistance to BESIVANCE develops via multiple-step mutations and occurs at a general frequency of <3.3x 10^-10 for Staphylococcus aureus and <7 x 10^-10 for Streptococcus pneumoniae.
- A.
  
  1
- B.
  
  2
- C.
  
  3